Hydroxychloroquine pre-exposure prophylaxis for COVID-19 among healthcare workers : Initial experience from India
Copyright: © 2022 Journal of Family Medicine and Primary Care..
Background: Hydroxychloroquine (HCQ) had generated considerable interest for coronavirus disease 2019 (COVID-19) prophylaxis. We conducted a prospective observational study at a tertiary care hospital in India, with dedicated COVID-19 care facilities.
Objectives: Primary objective was incidence of adverse effects, secondary objective being efficacy in preventing COVID-19.
Methods: Healthcare workers were recruited and grouped based on voluntary HCQ prophylaxis as per national guidelines. Side effects in HCQ group were graded in accordance with national cancer institute-common terminology criteria for adverse events (NCI-CTCAE) version 5.0. At 3-7-week follow-up, groups were compared for COVID-19 exposure, symptoms development and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RT-PCR results.
Results: Among 358 participants recruited, 216 (60.3%) were males and mean age was 31.2 ± 6.6 years. Chemoprophylaxis was initiated by 258 (72%) participants. After loading dose, 7 (2.7%) reported grade 2 and 1 (0.4%) grade 3 adverse effects. Discontinuation of HCQ due to side effects was reported in 11 (4.3%) participants. Electrocardiogram was done by 50 (19.4%) participants on HCQ; no abnormalities were noted. A total of 106 (41%) among those taking and 63 (63%) among those not taking HCQ were tested for SARS-CoV-2 due to influenza-like illness or significant exposure. Among all participants, 25 (6.9%, 95% confidence interval [CI] 4.3-9.6) developed COVID-19 during the study period. In the group taking HCQ, 10 (3.9%) tested positive compared to 15 (15%) in the group not taking HCQ (P < 0.001). Odds ratio with HCQ intake was 0.34 (95% CI 0.13-0.83, P = 0.01) and the number needed to treat was 12.
Conclusion: HCQ is safe at the recommended dose for pre-exposure prophylaxis of COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Journal of family medicine and primary care - 11(2022), 3 vom: 30. März, Seite 1140-1145 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kadnur, Harshith B [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Revised 05.04.2023 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.4103/jfmpc.jfmpc_1177_21 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM340246227 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM340246227 | ||
| 003 | DE-627 | ||
| 005 | 20231226004718.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4103/jfmpc.jfmpc_1177_21 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1134.xml |
| 035 | |a (DE-627)NLM340246227 | ||
| 035 | |a (NLM)35495846 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kadnur, Harshith B |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hydroxychloroquine pre-exposure prophylaxis for COVID-19 among healthcare workers |b Initial experience from India |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 05.04.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright: © 2022 Journal of Family Medicine and Primary Care. | ||
| 520 | |a Background: Hydroxychloroquine (HCQ) had generated considerable interest for coronavirus disease 2019 (COVID-19) prophylaxis. We conducted a prospective observational study at a tertiary care hospital in India, with dedicated COVID-19 care facilities | ||
| 520 | |a Objectives: Primary objective was incidence of adverse effects, secondary objective being efficacy in preventing COVID-19 | ||
| 520 | |a Methods: Healthcare workers were recruited and grouped based on voluntary HCQ prophylaxis as per national guidelines. Side effects in HCQ group were graded in accordance with national cancer institute-common terminology criteria for adverse events (NCI-CTCAE) version 5.0. At 3-7-week follow-up, groups were compared for COVID-19 exposure, symptoms development and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RT-PCR results | ||
| 520 | |a Results: Among 358 participants recruited, 216 (60.3%) were males and mean age was 31.2 ± 6.6 years. Chemoprophylaxis was initiated by 258 (72%) participants. After loading dose, 7 (2.7%) reported grade 2 and 1 (0.4%) grade 3 adverse effects. Discontinuation of HCQ due to side effects was reported in 11 (4.3%) participants. Electrocardiogram was done by 50 (19.4%) participants on HCQ; no abnormalities were noted. A total of 106 (41%) among those taking and 63 (63%) among those not taking HCQ were tested for SARS-CoV-2 due to influenza-like illness or significant exposure. Among all participants, 25 (6.9%, 95% confidence interval [CI] 4.3-9.6) developed COVID-19 during the study period. In the group taking HCQ, 10 (3.9%) tested positive compared to 15 (15%) in the group not taking HCQ (P < 0.001). Odds ratio with HCQ intake was 0.34 (95% CI 0.13-0.83, P = 0.01) and the number needed to treat was 12 | ||
| 520 | |a Conclusion: HCQ is safe at the recommended dose for pre-exposure prophylaxis of COVID-19 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a healthcare workers | |
| 650 | 4 | |a hydroxychloroquine | |
| 650 | 4 | |a pre-exposure prophylaxis | |
| 700 | 1 | |a Aggarwal, Anivita |e verfasserin |4 aut | |
| 700 | 1 | |a Soneja, Manish |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Komal |e verfasserin |4 aut | |
| 700 | 1 | |a Mittal, Ankit |e verfasserin |4 aut | |
| 700 | 1 | |a Nischal, Neeraj |e verfasserin |4 aut | |
| 700 | 1 | |a Tirlangi, Praveen |e verfasserin |4 aut | |
| 700 | 1 | |a Khan, Adil Rashid |e verfasserin |4 aut | |
| 700 | 1 | |a Desai, Devashish |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Ankesh |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Arvind |e verfasserin |4 aut | |
| 700 | 1 | |a Jorwal, Pankaj |e verfasserin |4 aut | |
| 700 | 1 | |a Biswas, Ashutosh |e verfasserin |4 aut | |
| 700 | 1 | |a Pandey, Ravindra Mohan |e verfasserin |4 aut | |
| 700 | 1 | |a Wig, Naveet |e verfasserin |4 aut | |
| 700 | 1 | |a Guleria, Randeep |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of family medicine and primary care |d 2012 |g 11(2022), 3 vom: 30. März, Seite 1140-1145 |w (DE-627)NLM23498807X |x 2249-4863 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2022 |g number:3 |g day:30 |g month:03 |g pages:1140-1145 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4103/jfmpc.jfmpc_1177_21 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2022 |e 3 |b 30 |c 03 |h 1140-1145 | ||